Every DEF 14A that Athira Pharma, Inc. (ATHA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ATHA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATHA filings page.
LeonaBio, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 22, 2026 at 8:00 a.m. Pacific Time. Holders of 9,393,514 shares of common stock outstanding as of May 1, 2026 may vote online, by phone, mail, or during the webcast.
Stockholders will elect three Class III directors (Kelly A. Romano, James A. Johnson and Natalie C. Holles), ratify Ernst & Young LLP as independent auditor for 2026, approve on an advisory basis executive compensation, and choose how often future advisory pay votes occur. The board recommends voting FOR all proposals and selecting a THREE-YEAR frequency for Say‑on‑Pay votes.
LeonaBio, Inc. is asking stockholders to approve several capital and governance proposals at a virtual special meeting on March 18, 2026. The company seeks approval to issue 5,502,402 shares of common stock upon exercise of a pre-funded warrant held by Sermonix, and to allow Sermonix and Perceptive to exercise their warrants even if their ownership exceeds 19.99%, as required by Nasdaq Rule 5635(b). Stockholders are also asked to approve a new 2026 Equity Incentive Plan with an initial reserve of 5,700,000 shares plus an evergreen increase, amend the charter to increase authorized common stock, and permit adjournment if more time is needed to secure votes. If key proposals fail, LeonaBio may owe Sermonix up to $7.5 million in redemptions and would have fewer shares available for future financings and incentives.